Open Access Highly Accessed Open Badges Research article

Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11-15 years: a randomised controlled study

Pierre Van Damme1*, Anna Moiseeva2, Igor Marichev2, Anne-Diane Kervyn3, Robert Booy4, Sherine Kuriyakose5, Andrew Brockway6, Su-Peing Ng7, Maarten Leyssen8 and Jeanne-Marie Jacquet8

Author Affiliations

1 Professor, Faculty of Medicine, Vaccine & Infectious Disease Institute (WHO Collaborating Centre), Centre for the Evaluation of Vaccination, Antwerpen, Belgium

2 Ministry of Health, Centre of Immunobiological Products, Kiev, Ukraine

3 Centre de Santé UCL, Clos Chapelle-aux-Champs, 30/39 1200 Brussels, Belgium

4 National Centre for Immunisation Research and Surveillance, The Children's Hospital at Westmead, NSW 2145, Australia; and The University of Sydney, NSW, Australia

5 GlaxoSmithKline Pharmaceuticals Ltd., Bangalore, India

6 GlaxoSmithKline Biologicals, Melbourne Victoria, Australia

7 GlaxoSmithKline Biologicals, Singapore

8 GlaxoSmithKline Biologicals, Wavre, Belgium

For all author emails, please log on.

BMC Infectious Diseases 2010, 10:357  doi:10.1186/1471-2334-10-357

Published: 20 December 2010



The standard three-dose schedule of hepatitis B vaccines is frequently not completed, especially in adolescents. A primary study has confirmed the equivalence of a two-dose schedule of an Adult formulation of hepatitis B vaccine [Group HBV_2D] to a three-dose schedule of a Paediatric formulation in adolescents (11-15 years) [Group HBV_3D]. This follow-up study evaluated the five year persistence of antibody response and immune memory against the hepatitis B surface (anti-HBs) antigens five years after completion of primary vaccination.


A total of 234 subjects returned at the Year 5 time point, of which 144 subjects received a challenge dose of hepatitis B vaccine. Blood samples were collected yearly and pre- and post-challenge dose to assess anti-HBs antibody concentrations.


At the end of five years, 79.5% (95% confidence interval [CI]: 71.7 - 86.1) and 91.4% (95% CI: 82.3 - 96.8) of subjects who received the two-dose and three-dose schedules, respectively had anti-HBs antibody concentrations ≥10 mIU/mL. Post-challenge dose, all subjects had anti-HBs antibody concentration ≥10 mIU/mL and >94% subjects had anti-HBs antibody concentration ≥100 mIU/mL. All subjects mounted a rapid anamnestic response to the challenge dose. Overall, the challenge dose was well-tolerated.


The two-dose schedule of hepatitis B vaccine confers long-term immunogenicity and shows evidence of immune memory for at least five years following vaccination.

Trial registration

Clinical Trials NCT00343915, NCT00524576